Edesa Biotech, Inc.
EDSA · XNASCIK 1540159fmd_0G75Q7WKW61H20MBJHVH515FEAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Sep 01, 2011 to Jun 30, 2026, 53 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 1 | 0 | 0 | 0 | 0 | – | – | – | – |
| Rental revenue | – | – | – | – | – | 10 | 1 | – | – | – |
| Cost of revenue | 1 | 1 | 0 | 0 | 0 | 0 | – | – | – | – |
| Gross profit | 0 | 0 | (0) | 0 | 0 | 0 | – | – | – | – |
| Research and development | 1 | 2 | 2 | 2 | 3 | 18 | 13 | 5 | 3 | 4 |
| Total operating expenses | 5 | 6 | 5 | 5 | 7 | – | – | – | – | – |
| Operating income | (4) | (5) | (5) | (5) | (6) | (24) | (18) | (9) | (7) | (8) |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – |
| Other non-operating income (expense) | 2 | (0) | 0 | 0 | 0 | 10 | 1 | 1 | 1 | 1 |
| Income before taxes | (3) | (5) | (5) | (5) | – | (13) | (18) | (8) | (6) | (7) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (3) | (5) | (5) | (5) | – | (13) | (18) | (8) | (6) | (7) |
| Net income | (3) | (5) | (5) | (5) | (6) | (13) | (18) | (8) | (6) | (7) |